Published in Biotech Business Week, June 8th, 2009
"With the introduction Of novel drugs and mechanisms of action comes the challenge of monitoring for new unreported adverse events. The side effect profile for aliskiren has not yet been fully described," wrote G.J. Peitz and colleagues.
The researchers concluded: "We describe the first apparent report of aliskiren-induced QT prolongation resulting ill torsades de pointes."
Peitz and colleagues...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.